GlassScriptPhysician profile
Kent S Hoffman
NPI 1396711289
$156,157.19
in general payments reported to CMS, 2019-2025
55 companies · $56K in 2025
The $56K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $11K · 2021: $2,515 · 2022: $3,144 · 2023: $6,427 · 2024: $60K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $98K · Travel and Lodging: $17K · Food and Beverage: $7,696 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $98,010.00 |
| Travel and Lodging | $16,709.53 |
| Food and Beverage | $7,696.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $118,984.87 | 2023-2025 | Brixadi |
| Indivior INC. | $19,982.59 | 2019-2025 | Sublocade |
| Allergan, INC. | $3,870.20 | 2019-2021 | |
| Sandoz INC. | $2,283.75 | 2019 | |
| Orexo US, INC. | $1,614.60 | 2019-2025 | Zubsolv |
| Abbvie INC. | $1,506.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $992.12 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Alkermes, INC. | $951.82 | 2019-2025 | Vivitrol, Vivitrol |
| Lilly USA, LLC | $873.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $632.14 | 2019-2025 | |
| Mdd US Operations, LLC | $534.54 | 2019-2020 | |
| Novo Nordisk INC | $503.99 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $472.40 | 2019-2022 | |
| Amgen INC. | $293.20 | 2019-2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $245.72 | 2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.